Acurx Receives Indian Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals, Inc., a prominent biopharmaceutical company based in Staten Island, New York, has recently achieved a significant milestone with the granting of a new patent by the Indian Patent Office. This development, announced in April 2025, pertains to their innovative DNA Polymerase IIIC Inhibitors and includes compositions-of-matter. This patent is part of a broader strategy by Acurx to secure intellectual property rights for their antimicrobial technologies across a range of countries. The Company has already obtained patents in the United States, Israel, Japan, and now India, with additional patents pending in other regions.

The Executive Chairman of Acurx, Robert J. DeLuccia, expressed his satisfaction with the progress. He emphasized the importance of expanding the Company’s reach into new markets, as they evolve their advanced, AI-supported drug discovery platform focused on second-generation DNA pol IIIC inhibitors. DeLuccia highlighted that their leading DNA pol IIIC inhibitor is ready to enter Phase 3 clinical trials for the oral treatment of C. difficile infection. Furthermore, he noted that their second-generation compounds are designed for systemic absorption, which offers potential for both oral and parenteral use. These compounds aim to address infections caused by gram-positive bacteria, including Staphylococcus aureus strains like MRSA, vancomycin-resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP), and Bacillus anthracis, the latter being a bioterrorism Category A threat-level pathogen.

Acurx Pharmaceuticals focuses its efforts on developing a novel class of small molecule antibiotics specifically targeted at challenging bacterial infections. Their strategy involves creating antibiotic candidates with a Gram-positive selective spectrum (GPSS®). This approach works by inhibiting the DNA replication process of Gram-positive bacteria, therefore leading to the death of these bacterial cells. The R&D pipeline at Acurx includes antibiotic candidates aimed at Gram-positive bacteria such as Clostridioides difficile, MRSA, VRE, DRSP, and anthrax.

The Company’s leading product candidate, ibezapolstat, is poised to commence Phase 3 trials for treating C. difficile infection, with plans for international clinical trials underway. Additionally, Acurx's preclinical projects include developing an oral product candidate for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Parallel to this, they are planning a development program for inhalation treatment aimed at anthrax.

Acurx Pharmaceuticals is committed to advancing its innovative drug pipeline and securing global patents to protect its intellectual property. Through strategic patent acquisitions and a focus on unmet medical needs, the Company is positioning itself to make significant contributions to antimicrobial therapy.